CARLSBAD, Calif.--(BUSINESS WIRE)--April 6, 2006--The Immune Response Corporation (OTCBB:IMNR - News) announced that its T-cell receptor peptide vaccine candidate, NeuroVax(TM), induces increased FOXP3 expression resulting in re-establishment of normal levels of the FOXP3+ regulatory T-cells believed to be important in controlling the development of multiple sclerosis (MS). Results of the recently completed open-label trial in MS patients were presented yesterday by Dr. Dennis Bourdette, Oregon Health and Sciences University (OHSU) Department of Neurology Chair, during an oral presentation at the 58th Annual Meeting of the American Academy of Neurology in San Diego, CA.
